预约演示
KSQ scores 'double-digit million' payment from Japan's Ono for preclinical cancer programs
2023-01-25
细胞疗法免疫疗法临床1期引进/卖出
KSQ Therapeutics' deal with Ono Pharmaceutical comes almost exactly two years after a deal with Takeda worth up to $100 million to develop two T-cell programs as well a discovery program to identify NK cell targets.
KSQ Therapeuticssigning a coOno PharmaceuticalKSQ Therapeutics has garnered interest from anotheTakedanese pharma. This time it’s Ono Pharmaceutical, which is handing over a “double-digit million” upfront payment for a number of preclinical oncology programs.
The research-stage DNA damage responseTakeda pKSQ Therapeutics identified using KSQ’s CRISPRomics platform technology. In return, Ono Pharmaceuticalsachusetts-based biotech will be eligible for milestone payments that could stretch into the “triple-digit millions” as well as royalties, the company said.
“This acquisition of multiple research-stage oncology programs by Ono is further validation of the power of our platform to identify novel oncology targets and develop potential first-in-class programs,” KSQ CEO Qasim Rizvi. "This is an important transaction for KSQ, enabling us to focus on our other programs. We look forward to watching Ono’s progress as they advance these programs toward clinical studies."
The aim of KSQ’s CRISPRomics platform is to decodKSQ-4279nomeUSP1 inhibitorUSP1identify potential gene targets for oncology and autoimmune disease therapies. As well as KSQ-4279, the biotech has used the platform tPARPrk on a pair of preclinical T-cell therapies, while a Treg program remains in the discovery stages.
The Ono traKSQction comes almost exactly two years after a deal with Takeda worth up to $100 million to develop twautoimmune diseaseas well a discovery proKSQ-4279identify natural killer cell targets. However, KSQ had been quiet on the collaboration since then.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。